ProCE Banner Series

Individualizing Therapy in Low-Risk MDS: New Evidence and Options for Your Patients

In this 1-hour CME-certified webinar, expert faculty will join us live from Chicago to discuss the latest data on managing anemia in patients with low-risk MDS. Don’t miss the opportunity to get your pressing questions answered. Register now!

Not an official event of the 2024 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.

  AMA
Who Should Attend

This program is intended for hematologists, oncologists, and other healthcare professionals treating patients with myelodysplastic syndromes.

All Events

Individualizing Therapy in Low-Risk MDS: New Evidence and Options for Your Patients

Past Events

June

02

2024

6:30 AM - 7:30 AM Central Time (CT)

Virtual

Faculty

ProCE Banner Faculty
Rami Komrokji, MD

Section Head – Leukemia & MDS, Vice Chair
Department of Malignant Hematology
Moffitt Cancer Center
Tampa, Florida

ProCE Banner Faculty
Maximilian Stahl, MD

Department of Medical Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

 

ProCE Banner Faculty
Amer Zeidan, MBBS, MHS

Associate Professor of Medicine (Hematology)
Chief, Division of Hematologic Malignancies
Yale Comprehensive Cancer Center and Smilow Cancer Hospital
New Haven, Connecticut

Topics

Myelodysplastic syndromes

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
This program aims to improve learners’ knowledge, confidence, and competence in aligning clinical practice with evolving standards of care for patients with lower-risk myelodysplastic syndromes. 

Target Audience
This program is intended for hematologists, oncologists, and other healthcare professionals treating patients with myelodysplastic syndromes.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Plan first-line individualized therapeutic strategies for patients with LR-MDS based on new clinical data/approvals, new WHO and ICC guidelines, patient and disease characteristics, and validated risk stratification tools 
  • Employ the latest approvals and recent clinical trial results on dosing frequency and escalation, and durability of response when considering treatment of patients with very low–risk, low-risk, or intermediate-risk MDS 
  • Develop evidence-based and equitable care plans that recognize and identify early ESA treatment failure in all patients with LR-MDS 
  • Appraise ongoing clinical trials evaluating newer agents and approaches for the treatment of patients with lower-risk MDS for appropriate and inclusive patient enrollment

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by an educational grant from Bristol Myers Squibb.